Related Experiment Video
Updated: Jun 27, 2026
14:55
Methods to Quantify Pharmacologically Induced Alterations in Motor Function in Human Incomplete SCI
Published on: April 18, 2011
14.3K
Pharmacological and device-based interventions for paraplegia: A ClinicalTrials.gov-based analysis
Nasser M Alorfi1, Fahad S Alshehri1,2, Saad M Wali1
1Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Medicine
|February 27, 2026
Summary
Clinical trials for paraplegia increasingly focus on device-based and pharmacological interventions to improve mobility and reduce complications. Standardization of trial design and outcomes is crucial for advancing effective paraplegia treatments.
Area of Science:
- Neuroscience and Rehabilitation Medicine
- Clinical Trial Analysis
- Medical Technology Assessment
Background:
- Paraplegia, caused by spinal cord injury or neurological disease, necessitates advanced long-term care and rehabilitation strategies.
- Improving mobility, managing complications, and enhancing quality of life are key goals in paraplegia management.
- A systematic analysis of clinical trials is vital to understand current research trends and therapeutic advancements.
Purpose of the Study:
- To systematically analyze clinical trials registered on ClinicalTrials.gov investigating interventions for paraplegia.
- To categorize studies by intervention type, class, and primary outcome focus.
- To identify trends in pharmacological, device-based, and procedural therapies for paraplegia.
Main Methods:
- Retrospective analysis of 84 paraplegia-related clinical trials registered on ClinicalTrials.gov.
- Categorization of studies by trial type (interventional/observational) and intervention class (pharmacological, device-based, behavioral, biological, procedural).
- Descriptive analysis of sample size, enrollment, and primary outcome categories, with emphasis on interventional trials.
Main Results:
- Out of 84 trials, 61 were interventional, focusing on device-based (n=30) and pharmacological (n=10) interventions.
- Device-based therapies included exoskeletons, functional electrical stimulation, and robotics.
- Pharmacological interventions targeted spasticity, neuroprotection, and cardiovascular regulation; mobility/function was the most common outcome.
- Many studies reported small sample sizes, indicating a need for larger, more standardized trials.
Conclusions:
- Paraplegia research is shifting towards pharmacological and device-supported interventions to enhance motor recovery and mitigate secondary disability.
- Current trials show promising directions for optimizing long-term paraplegia management.
- Standardization in clinical trial design and outcome reporting is essential for improving therapeutic effectiveness and clinical applicability.
More Related Videos
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications